drugset / Trial / NCT02133625

A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors

NCT02133625

Phase 1 Completed 14 enrolled Dana-Farber Cancer Institute
Non-randomizedSingle-groupTreatment

Summary

The proposed investigation is a Phase 1 trial to determine the safety, tolerability, and maximum tolerated dose (MTD) of the combination of pioglitazone ( and carboplatin patients with advanced or metastatic solid malignancies.

Timeline

Start
2011-08
Primary completion
2016-03
Completion
2026-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule Intravenous
Subject Pioglitazone Small molecule 45 mg Oral